edp1815
Small moleculeexperimentalCOVID-19
Clinical trial activity
8 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Nov 19, 2018 (NCT03733353)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05682222 | Phase 1 | Jun 27, 2022 | Evelo Biosciences |
| NCT05439941 | Phase 2 | Jun 6, 2022 | Evelo Biosciences, Oregon Medical Research Center |
| NCT05121480 | Phase 2 | Nov 30, 2021 | Evelo Biosciences, Oregon Medical Research Center |
| NCT05066373 | Phase 1 | Aug 9, 2021 | BDD Pharma Ltd, Evelo Biosciences |
| NCT04603027 | Phase 2 | Sep 21, 2020 | Evelo Biosciences, Oregon Medical Research Center |
| NCT04488575 | Phase 2 | Aug 26, 2020 | Evelo Biosciences, Rutgers University |
| NCT04393246 | Phase 2/Phase 3 (Phase 3) | May 20, 2020 | University of Cambridge |
| NCT03733353 | Phase 1 | Nov 19, 2018 | Evelo Biosciences |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Evelo Biosciences | Academic/Hospital | 7 | 7 | 2 | 2018 |
| Oregon Medical Research Center | For profit | 3 | 0 | 1 | 2020 |
| BDD Pharma Ltd | For profit | 1 | 0 | 1 | 2021 |
| Rutgers University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Cambridge | Academic/Hospital | 1 | 1 | 1 | 2020 |
5 organizations
Page 1 / 1